What Happened?
Shares of biotechnology company Moderna (NASDAQ: MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results. Despite this, Barclays seems to be exercising caution, downgrading the stock to equal weight from overweight earlier in the morning. The firm cited "policy risks, fewer clinical catalysts, and broader economic uncertainties that could limit its upside.".
Is now the time to buy Moderna? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Moderna’s shares are extremely volatile and have had 40 moves greater than 5% over the last year. But moves this big are rare even for Moderna and indicate this news significantly impacted the market’s perception of the business.
Moderna is down 15.1% since the beginning of the year, and at $35.69 per share, it is trading 78.6% below its 52-week high of $166.61 from May 2024. Investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at an investment worth $1,887.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
